Month: December 2020

Reference is made to the announcement by Saga Pure ASA on 21 December 2020 concerning a private placement with total gross proceeds of NOK 87 million and a contemplated subsequent offering (the “Subsequent Offering“).Date on which the terms of the Subsequent Offering was announced: 21 December 2020Last day including right: 21 December 2020First day excluding right: 22 December 2020Record date: 23 December 2020Board resolution date: Not yet determinedMaximum number of new shares: 4,900,000Subscription price: NOK 2.90Shall the rights be listed: NoLaunch of the Subsequent Offering will be conditional upon; (i) the prevailing market price of the Company’s shares, (ii) relevant corporate resolutions being passed by the Company’s Board of Directors, and (iii) approval and publication of a prospectus by the Norwegian...

AB “Ignitis grupė” (hereinafter – the Company) publishes its reporting dates for 2021, including the General Meeting of Shareholders:   Upon publication of the annual results for the year 2020, as well as the half-year and interim results for 2021, on the dates to be set at a later stage, the Company will organize earning calls. Furthermore, during the course of the first quarter of 2021, the Company expects to present the strategic plan for 2021-2024.The Company reserves the right to revise the dates and would notify the market in due time of any changes.For additional information, please contact:CommunicationsArtūras Ketlerius+370 620 76076arturas.ketlerius@ignitis.ltInvestor RelationsAinė Riffel-Grinkevičienė+370 643 14925aine.riffel@ignitis.lt

AB „Ignitis grupė” (toliau – Bendrovė) skelbia rezultatų skelbimo 2021 m., įtraukiant ir visuotinio akcininko susirinkimo, datas:Paskelbus 2020 m. metinį pranešimą, 2021 m. pusmečio ir tarpinius rezultatus, vėliau nustatytomis datomis, Bendrovė rengs rezultatų pristatymo skambučius. Papildomai, per pirmąjį 2021 m. ketvirtį, Bendrovė ketina pristatyti strateginį planą 2021-2024 m. laikotarpiui.Bendrovė pasilieka teisę tikslinti datas ir apie pokyčius informuoti rinkos dalyvius.Dėl papildomos informacijos, prašome kreiptis:KomunikacijaArtūras Ketlerius+370 620 76076arturas.ketlerius@ignitis.ltRyšiai su investuotojaisAinė Riffel-Grinkevičienė+370 643 14925aine.riffel@ignitis.lt

Amsterdam/’s-Hertogenbosch, the Netherlands, 22 December 2020Van Lanschot Kempen is pleased to announce that its regulators have issued a declaration of no objection for its takeover and proposed integration of Hof Hoorneman Bankiers into Van Lanschot Kempen. The takeover, announced on 18 August 2020, is expected to complete in January 2021.With €2.0 billion in client assets, Hof Hoorneman Bankiers offers private banking, online wealth management and settlement-only services as its core activities. It also manages a number of own investment funds in which mostly its own clients invest.The takeover will increase Van Lanschot Kempen’s client assets within Van Lanschot Private Banking and Evi. It also offers scope for significant economies of scale and further growth, as Hof Hoorneman Bankiers clients will be gaining access to a broader...

Amsterdam/’s-Hertogenbosch, 22 december 2020Van Lanschot Kempen is verheugd te kunnen aankondigen dat de toezichthouders verklaringen van geen bezwaar hebben verleend voor de overname en de beoogde integratie van Hof Hoorneman Bankiers in Van Lanschot Kempen. De overname, die op 18 augustus 2020 werd aangekondigd, zal naar verwachting in januari 2021 worden afgerond.Hof Hoorneman Bankiers heeft € 2,0 miljard client assets en haar kernactiviteiten omvatten private banking, online vermogensbeheer en settlement only-diensten. Hof Hoorneman Bankiers beheert een aantal eigen beleggingsfondsen waarin voornamelijk de eigen klanten beleggen. Met deze overname vergroot Van Lanschot Kempen de client assets binnen Van Lanschot Private Banking en Evi. Daarnaast is er ruimte voor het realiseren van aanzienlijke schaalvoordelen en verdere groei door...

December 22, 2020AkzoNobel share buyback (December 14, 2020 – December 18, 2020)AkzoNobel (AKZA; AKZOY) has repurchased 196,777 of its own common shares in the period from December 14, 2020, up to and including December 18, 2020, at an average price of €86.57 per share. The consideration of the repurchase was €17.04 million.This is part of a repurchase program announced on October 21, 2020. AkzoNobel intends to repurchase common shares up to a value of €300 million. The total number of shares repurchased under this program to date is 401,124 ordinary shares for a total consideration of €35.07 million.The share buyback is due to be completed in the first half of 2021. The company has engaged a third party to manage the program and perform transactions on its behalf. It is intended that the shares will be cancelled following repurchase.The...

AB “Ignitis grupė” financial calendar 2021AB “Ignitis grupė” (hereinafter – the Company) publishes its reporting dates for 2021, including the General Meeting of Shareholders:   Upon publication of the annual results for the year 2020, as well as the half-year and interim results for 2021, on the dates to be set at a later stage, the Company will organize earning calls. Furthermore, during the course of the first quarter of 2021, the Company expects to present the strategic plan for 2021-2024.The Company reserves the right to revise the dates and would notify the market in due time of any changes.For additional information, please contact:CommunicationsArtūras Ketlerius+370 620 76076arturas.ketlerius@ignitis.ltInvestor RelationsAinė Riffel-Grinkevičienė+370 643 14925aine.riffel@ignitis.lt

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Healthcare Conference taking place virtually on Monday January 11, 2021 at 8 a.m. EST (1 p.m. GMT / 9 p.m. HKT).The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under “Events, Circulars & Forms.” Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter, for 90 days.About Chi-MedChi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the...

Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA).Polyphor’s inhaled murepavadin is a novel class antibiotic that specifically targets Pseudomonas aeruginosa lung infections in people with cystic fibrosis (CF).Phase I development in healthy volunteers is jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI).ALLSCHWIL, Switzerland, Dec. 22, 2020 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) today announced that the UK Medicines and Healthcare products regulatory agency (MHRA) has granted a CTA (Clinical Trial Authorization) to start the first-in-human Phase I study of its novel class antibiotic...

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCHSinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced changes to its management team. Julie Rassat joins Sinch in a new role as VP Integration and Sanjay Goyal joins the Sinch management team as President and Managing Director, India.Julie Rassat joins Sinch with a wealth of experience ranging from complex multi-country deals to smaller bolt-on acquisitions. She has worked on more than 30 transactions in technology, media and fintech, and joins Sinch from a previous engagement with Global PMI Partners, a leading global consultancy specialized in post-merger integration. Prior to this, Julie was Senior Director, International Acquisitions Integration at ThomsonReuters.As the President and Co-Founder of ACL Mobile, Sanjay Goyal brings 20+...